Epithelial‐to‐mesenchymal transition (EMT) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy

Adjuvant chemotherapy has long been indicated to extend survival in completely resected stage IB to IIIA non-small cell lung cancer (NSCLC). However, there is accumulating evidence that chemotherapy or chemoradiotherapy can induce epithelial-to-mesenchymal transition (EMT) in disseminated or circula...

Full description

Saved in:
Bibliographic Details
Main Authors: Poh, Mau Ern, Liam, Chong Kin, Mun, Kein Seong, Chai, Chee Shee, Wong, Chee Kuan, Tan, Jiunn Liang, Loh, Thian Chee, Chin, Ka Kiat
Format: Article
Published: Wiley Open Access 2019
Subjects:
Online Access:http://eprints.um.edu.my/23749/
https://doi.org/10.1111/1759-7714.13156
Tags: Add Tag
No Tags, Be the first to tag this record!
id my.um.eprints.23749
record_format eprints
spelling my.um.eprints.237492021-03-23T02:26:07Z http://eprints.um.edu.my/23749/ Epithelial‐to‐mesenchymal transition (EMT) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy Poh, Mau Ern Liam, Chong Kin Mun, Kein Seong Chai, Chee Shee Wong, Chee Kuan Tan, Jiunn Liang Loh, Thian Chee Chin, Ka Kiat R Medicine Adjuvant chemotherapy has long been indicated to extend survival in completely resected stage IB to IIIA non-small cell lung cancer (NSCLC). However, there is accumulating evidence that chemotherapy or chemoradiotherapy can induce epithelial-to-mesenchymal transition (EMT) in disseminated or circulating NSCLC cells. Here, we describe the first case of EMT as the cause of recurrence and metastasis in a patient with resected stage IIB lung adenosquamous carcinoma after adjuvant chemotherapy. We review the literature and explore the possible mechanisms by which EMT occurs in disseminated tumor cells (DTC) or circulating tumor cells (CTC) in response to adjuvant chemotherapy (cisplatin) as a stressor. We also explore the possible therapeutic strategies to reverse EMT in patients with recurrence. In summary, although adjuvant cisplatin-based chemotherapy in resected NSCLC does extend survival, it may lead to the adverse phenomenon of EMT in disseminated tumor cells (DTC) or circulating tumor cells (CTC) causing recurrence and metastasis. © 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd Wiley Open Access 2019 Article PeerReviewed Poh, Mau Ern and Liam, Chong Kin and Mun, Kein Seong and Chai, Chee Shee and Wong, Chee Kuan and Tan, Jiunn Liang and Loh, Thian Chee and Chin, Ka Kiat (2019) Epithelial‐to‐mesenchymal transition (EMT) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy. Thoracic Cancer, 10 (9). pp. 1841-1845. ISSN 1759-7706 https://doi.org/10.1111/1759-7714.13156 doi:10.1111/1759-7714.13156
institution Universiti Malaya
building UM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Malaya
content_source UM Research Repository
url_provider http://eprints.um.edu.my/
topic R Medicine
spellingShingle R Medicine
Poh, Mau Ern
Liam, Chong Kin
Mun, Kein Seong
Chai, Chee Shee
Wong, Chee Kuan
Tan, Jiunn Liang
Loh, Thian Chee
Chin, Ka Kiat
Epithelial‐to‐mesenchymal transition (EMT) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy
description Adjuvant chemotherapy has long been indicated to extend survival in completely resected stage IB to IIIA non-small cell lung cancer (NSCLC). However, there is accumulating evidence that chemotherapy or chemoradiotherapy can induce epithelial-to-mesenchymal transition (EMT) in disseminated or circulating NSCLC cells. Here, we describe the first case of EMT as the cause of recurrence and metastasis in a patient with resected stage IIB lung adenosquamous carcinoma after adjuvant chemotherapy. We review the literature and explore the possible mechanisms by which EMT occurs in disseminated tumor cells (DTC) or circulating tumor cells (CTC) in response to adjuvant chemotherapy (cisplatin) as a stressor. We also explore the possible therapeutic strategies to reverse EMT in patients with recurrence. In summary, although adjuvant cisplatin-based chemotherapy in resected NSCLC does extend survival, it may lead to the adverse phenomenon of EMT in disseminated tumor cells (DTC) or circulating tumor cells (CTC) causing recurrence and metastasis. © 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd
format Article
author Poh, Mau Ern
Liam, Chong Kin
Mun, Kein Seong
Chai, Chee Shee
Wong, Chee Kuan
Tan, Jiunn Liang
Loh, Thian Chee
Chin, Ka Kiat
author_facet Poh, Mau Ern
Liam, Chong Kin
Mun, Kein Seong
Chai, Chee Shee
Wong, Chee Kuan
Tan, Jiunn Liang
Loh, Thian Chee
Chin, Ka Kiat
author_sort Poh, Mau Ern
title Epithelial‐to‐mesenchymal transition (EMT) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy
title_short Epithelial‐to‐mesenchymal transition (EMT) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy
title_full Epithelial‐to‐mesenchymal transition (EMT) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy
title_fullStr Epithelial‐to‐mesenchymal transition (EMT) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy
title_full_unstemmed Epithelial‐to‐mesenchymal transition (EMT) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy
title_sort epithelial‐to‐mesenchymal transition (emt) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy
publisher Wiley Open Access
publishDate 2019
url http://eprints.um.edu.my/23749/
https://doi.org/10.1111/1759-7714.13156
_version_ 1695531081626812416
score 13.164666